This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)

Tipranks - Tipranks - Thu Jun 4, 8:44AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vera Therapeutics (VERA), OrthoPediatrics (KIDS) and Disc Medicine (IRON) with bullish sentiments.

Claim 55% Off TipRanks

Vera Therapeutics (VERA)

In a report released yesterday, Paul Choi from Goldman Sachs maintained a Buy rating on Vera Therapeutics, with a price target of $90.00. The company’s shares closed last Wednesday at $31.31.

According to TipRanks.com, Choi is a 4-star analyst with an average return of 8.2% and a 53.5% success rate. Choi covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Arvinas Holding Company, and Corvus Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vera Therapeutics with a $79.00 average price target, implying a 152.7% upside from current levels. In a report issued on May 22, J.P. Morgan also maintained a Buy rating on the stock with a $86.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

OrthoPediatrics (KIDS)

Canaccord Genuity analyst Caitlin Roberts maintained a Buy rating on OrthoPediatrics yesterday and set a price target of $25.00. The company’s shares closed last Wednesday at $16.84.

According to TipRanks.com, Roberts is a 1-star analyst with an average return of -4.0% and a 32.8% success rate. Roberts covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Zimmer Biomet Holdings, and Smith & Nephew Snats. ;'>

OrthoPediatrics has an analyst consensus of Strong Buy, with a price target consensus of $24.63.

Disc Medicine (IRON)

Truist Financial analyst Danielle Brill maintained a Buy rating on Disc Medicine today. The company’s shares closed last Wednesday at $67.88, close to its 52-week high of $68.73.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 12.2% and a 51.8% success rate. Brill covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Rapport Therapeutics, Inc., and Praxis Precision Medicines. ;'>

Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $103.14, implying a 51.7% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $100.00 price target.

Read More on VERA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).